JP2021535749A5 - - Google Patents

Info

Publication number
JP2021535749A5
JP2021535749A5 JP2021512906A JP2021512906A JP2021535749A5 JP 2021535749 A5 JP2021535749 A5 JP 2021535749A5 JP 2021512906 A JP2021512906 A JP 2021512906A JP 2021512906 A JP2021512906 A JP 2021512906A JP 2021535749 A5 JP2021535749 A5 JP 2021535749A5
Authority
JP
Japan
Prior art keywords
subject
peptides
cancer
amino acid
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021512906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535749A (ja
Filing date
Publication date
Priority claimed from GBGB1814362.8A external-priority patent/GB201814362D0/en
Application filed filed Critical
Publication of JP2021535749A publication Critical patent/JP2021535749A/ja
Publication of JP2021535749A5 publication Critical patent/JP2021535749A5/ja
Priority to JP2025019485A priority Critical patent/JP2025069437A/ja
Pending legal-status Critical Current

Links

JP2021512906A 2018-09-04 2019-09-03 ワクチン組成物を調製するためのプロセス Pending JP2021535749A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025019485A JP2025069437A (ja) 2018-09-04 2025-02-07 ワクチン組成物を調製するためのプロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1814362.8A GB201814362D0 (en) 2018-09-04 2018-09-04 Composition and process for preparing vaccine
GB1814362.8 2018-09-04
PCT/EP2019/073481 WO2020048995A1 (en) 2018-09-04 2019-09-03 Process for preparing vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025019485A Division JP2025069437A (ja) 2018-09-04 2025-02-07 ワクチン組成物を調製するためのプロセス

Publications (2)

Publication Number Publication Date
JP2021535749A JP2021535749A (ja) 2021-12-23
JP2021535749A5 true JP2021535749A5 (cg-RX-API-DMAC7.html) 2022-11-28

Family

ID=63920945

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021512906A Pending JP2021535749A (ja) 2018-09-04 2019-09-03 ワクチン組成物を調製するためのプロセス
JP2025019485A Pending JP2025069437A (ja) 2018-09-04 2025-02-07 ワクチン組成物を調製するためのプロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025019485A Pending JP2025069437A (ja) 2018-09-04 2025-02-07 ワクチン組成物を調製するためのプロセス

Country Status (17)

Country Link
US (3) US20200069786A1 (cg-RX-API-DMAC7.html)
EP (1) EP3847185A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021535749A (cg-RX-API-DMAC7.html)
KR (1) KR20210086610A (cg-RX-API-DMAC7.html)
CN (1) CN113383009A (cg-RX-API-DMAC7.html)
AU (1) AU2019334261B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004075A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110923A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000534A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021004028A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190669A1 (cg-RX-API-DMAC7.html)
GB (1) GB201814362D0 (cg-RX-API-DMAC7.html)
IL (1) IL281220A (cg-RX-API-DMAC7.html)
MA (1) MA53544A (cg-RX-API-DMAC7.html)
MX (1) MX2021002543A (cg-RX-API-DMAC7.html)
SG (1) SG11202101881UA (cg-RX-API-DMAC7.html)
WO (1) WO2020048995A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018307A2 (pt) 2017-03-03 2020-03-31 Treos Bio Zrt Plataforma para identificação de peptídeos imunogênicos baseada em população
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
CN113329761A (zh) 2018-09-04 2021-08-31 特雷斯生物有限公司 肽疫苗
MX2022001206A (es) * 2019-07-30 2022-05-03 Univ Health Network Receptores de linfocitos t y metodos de uso de los mismos.
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
US20230190902A1 (en) * 2020-05-29 2023-06-22 Children's National Medical Center Identification of hla-restricted prame peptide epitopes, prame-specific t cells suitable for "off-the-shelf" treatment of cancer expressing prame
CN111617238B (zh) * 2020-06-02 2022-12-13 苏州药明康德新药开发有限公司 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法
EP3945320A1 (en) * 2020-07-29 2022-02-02 Corporació Sanitària Parc Taulí Improved epitope for detecting and/or quantifying autoantibodies against alpha-fetoprotein
EP4236981A1 (en) * 2020-10-28 2023-09-06 Follicum AB Peptides for use in skin and hair pigmentation
KR20240007162A (ko) * 2021-04-14 2024-01-16 티스캔 테라퓨틱스, 인크. Magec2 면역원성 펩티드, magec2 면역원성 펩티드를 인식하는 결합 단백질 및 이의 용도
CN113144181B (zh) * 2021-04-20 2022-07-19 徐州医科大学 一种靶向b7h3的dna疫苗、制备方法及应用
CN114195861A (zh) * 2022-01-05 2022-03-18 许昌学院 亲和肽
IT202200006785A1 (it) * 2022-04-06 2023-10-06 Istituto Naz Tumori Irccs Fondazione G Pascale Analoghi di antigeni tumorali da microbiota e usi relativi
CN115785211B (zh) * 2022-06-10 2024-09-24 河北博海生物工程开发有限公司 肺癌特异性分子靶标04及其用途
CN115785204B (zh) * 2022-06-10 2024-02-13 河北博海生物工程开发有限公司 肺癌特异性分子靶标08及其用途
WO2025227519A1 (zh) * 2024-04-29 2025-11-06 北京臻知医学科技有限责任公司 一种肿瘤疫苗及其应用
WO2026125390A1 (en) 2024-12-09 2026-06-18 Vib Vzw Fthl17 immunogen and tcr

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
GB0520067D0 (en) * 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
CA2665816C (en) * 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
WO2012051282A2 (en) * 2010-10-14 2012-04-19 The Ohio State University Research Foundation Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
BR112019018307A2 (pt) 2017-03-03 2020-03-31 Treos Bio Zrt Plataforma para identificação de peptídeos imunogênicos baseada em população
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine

Similar Documents

Publication Publication Date Title
ES2836273T3 (es) Método para el tratamiento del cáncer
JP2016156828A5 (cg-RX-API-DMAC7.html)
JP2021533777A5 (cg-RX-API-DMAC7.html)
MX2022011411A (es) Proteinas de union a antigeno que se unen especificamente a mage-a.
CN109152813B (zh) 作为靶标以及用于胆囊癌和胆管癌以及其他癌症免疫治疗的新型肽、肽组合物
JP2020500523A5 (cg-RX-API-DMAC7.html)
BR112019020959A2 (pt) peptídeos e combinações dos mesmos para uso na imunoterapia contra câncer
JP2022050398A (ja) 異なるタイプのがんに対する免疫療法で使用するための非標準起源のペプチドおよびペプチド組み合わせ
JP2016505635A5 (cg-RX-API-DMAC7.html)
IL268278B1 (en) New peptides and their combinations for immunotherapy against ovarian cancer and other cancers
JP2017122120A5 (cg-RX-API-DMAC7.html)
CN113383009A (zh) 制备疫苗组合物的方法
JP2017531427A5 (cg-RX-API-DMAC7.html)
TW201841934A (zh) 用於治療癌症免疫治療的新穎肽及其肽組合物
IL292864A (en) New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer
EP3408395A1 (en) Personalized delivery vector-based immunotherapy and uses thereof
JP2021502083A5 (cg-RX-API-DMAC7.html)
RU2016137834A (ru) КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu
EP3666793A3 (en) Combined t cell receptor gene therapy of cancer against mhc i and mhc ii-restricted epitopes of the tumor antigen ny-eso-1
JP2021500406A5 (cg-RX-API-DMAC7.html)
BR112020027021A2 (pt) Peptídeo, anticorpo, receptor de célula t, célula hospedeira recombinante, método in vitro de produção de linfócitos t ativados, composição farmacêutica, método de produção do peptídeo, uso do peptídeo e kit
US20250092104A1 (en) Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods
AU2020264365C1 (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
CA3108578A1 (en) B*44 restricted peptides for use in immunotherapy against cancers and related methods
US20220251544A1 (en) Methods and compositions for identifying neoantigens for use in treating and preventing cancer